PMID- 19467767
OWN - NLM
STAT- MEDLINE
DCOM- 20091022
LR  - 20131121
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 145
IP  - 2
DP  - 2009 Aug
TI  - Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a 
      preliminary study.
PG  - 177-9
LID - 10.1016/j.ejogrb.2009.04.025 [doi]
AB  - OBJECTIVE: Uncomplicated pelvic inflammatory disease (PID) is a common disease 
      caused by numerous pathogens: sexually transmitted infections (such as Chlamydia 
      trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and 
      other organisms from the vaginal flora. It is currently treated by oral route and 
      most present protocols recommend ofloxacin plus metronidazole (MET). The CDC 2006 
      Guidelines suggested that levofloxacin (LEV) can be a substitute for ofloxacin. 
      This study aimed to evaluate the efficacy and safety of LEV-MET in the treatment 
      of uncomplicated PID. STUDY DESIGN: The first 40 cases of uncomplicated PID were 
      prospectively evaluated (June 2006 to December 2007). Diagnosis was based on the 
      clinical signs and microbial findings. If present (N=8), IUD were removed and 
      cultured. Treatment consisted of LEV 500mg OD+MET 500mg BID by oral route for 14 
      days. Visits took place at the end of therapy (EOT) and at follow-up (FU) 4-6 
      weeks later. The endpoints were clinical resolution (at the EOT and FU) and 
      bacteriological eradication (at the EOT). RESULTS: 10 cases of bacterial 
      vaginosis were found and 35 pathogens (E. coli: 12, anaerobes: 5; C. trachomatis: 
      5; M. hominis: 5; U. urealyticum: 3; others: 5) were isolated in the cervix. 37 
      patients were evaluable at the EOT: 27 were clinically cured and 10 significantly 
      improved; all pathogens were eradicated. At FU, all 35 evaluable patients were 
      clinically cured. Drug-related adverse events (AEs) occurred in 9 cases: 1 
      patient discontinued (myalgia and tendonitis) while other AEs consisted of nausea 
      or diarrhea. CONCLUSION: This preliminary study has shown that a 14-day course of 
      oral LEV-MET is effective and well-tolerated in the treatment of outpatients with 
      uncomplicated PID.
FAU - Judlin, Philippe
AU  - Judlin P
AD  - Department of Obstetrics, Gynecology & Reproduction, Maternite Regionale 
      Universitaire, University Henri-Poincare, Nancy, France. 
      p.judlin@maternite.chu-nancy.fr
FAU - Thiebaugeorges, Olivier
AU  - Thiebaugeorges O
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20090520
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Anti-Bacterial Agents)
RN  - 140QMO216E (Metronidazole)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - A4P49JAZ9H (Ofloxacin)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Chlamydia Infections/drug therapy
MH  - Female
MH  - Humans
MH  - *Levofloxacin
MH  - Metronidazole/*administration & dosage
MH  - Ofloxacin/*administration & dosage
MH  - Pelvic Inflammatory Disease/*drug therapy
MH  - Sexually Transmitted Diseases/drug therapy
MH  - Vaginosis, Bacterial/drug therapy
EDAT- 2009/05/27 09:00
MHDA- 2009/10/23 06:00
CRDT- 2009/05/27 09:00
PHST- 2008/07/23 00:00 [received]
PHST- 2009/02/20 00:00 [revised]
PHST- 2009/04/21 00:00 [accepted]
PHST- 2009/05/27 09:00 [entrez]
PHST- 2009/05/27 09:00 [pubmed]
PHST- 2009/10/23 06:00 [medline]
AID - S0301-2115(09)00300-5 [pii]
AID - 10.1016/j.ejogrb.2009.04.025 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2009 Aug;145(2):177-9. doi: 
      10.1016/j.ejogrb.2009.04.025. Epub 2009 May 20.